SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Zydus Group aims two more novel drugs by 2020

10 Jun 2013 Evaluate

Zydus Cadila aims to launch at least two more novel drugs out of the 20 currently under discovery research programmes to become successful by 2020. It is currently working in the areas of metabolic disorders, oncology and inflammatory disorders. The company is planning to finance its drug discovery programmes, through internal resources.

A part of the Zydus Group, Cadila Healthcare had received regulatory approval to market its diabetes drug, Lipaglyn, in India last week. It expects the drug to be a blockbuster and clock over $1 billion sales a year when sold globally.

Zydus Lifesciences Share Price

937.65 -4.90 (-0.52%)
20-Apr-2026 14:45 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1669.20
Dr. Reddys Lab 1233.00
Cipla 1232.25
Zydus Lifesciences 937.65
Lupin 2328.25
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×